Orofar Ultra (Flurbiprofen)

Flurbiprofen works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes. This blockade reduces the production of prostaglandins, which are key mediators of inflammation, pain, and fever, thereby decreasing peripheral sensitisation of pain receptors and limiting inflammatory swelling.

The specific dose of Orofar Ultra is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and individual risk factors. Typical adult dosing ranges for flurbiprofen are described in the product label, but the exact regimen should always follow the prescriber’s instructions.

Flurbiprofen is generally avoided during the third trimester of pregnancy because it may affect fetal cardiovascular function. Use during earlier stages should be considered only if the potential benefit outweighs the risk. Limited data are available for breastfeeding; caution is advised, and a healthcare professional should evaluate the need for therapy.

To place an order, submit an enquiry on the Orofar Ultra product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Flurbiprofen shares the core anti‑inflammatory mechanism of other NSAIDs such as ibuprofen and naproxen but is often noted for a slightly longer half‑life, which may allow less frequent dosing. Its potency in COX inhibition can provide effective pain control, yet the safety profile—including gastrointestinal and renal risks—remains comparable to other agents in the class.

Orofar Ultra tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with excessive heat or humidity to maintain stability.

Orofar Ultra is taken orally with a full glass of water. It may be taken with or without food, although taking it with meals can reduce the likelihood of gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include gastrointestinal bleeding or ulceration, severe renal impairment, hepatotoxicity, and rare but life‑threatening allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for signs of these events, especially if they have pre‑existing risk factors.

Orofar Ultra should be avoided in individuals with known hypersensitivity to flurbiprofen or any NSAID, those with active peptic ulcer disease, severe heart failure, uncontrolled hypertension, advanced renal or hepatic impairment, and in the third trimester of pregnancy. Consultation with a healthcare professional is essential before initiating therapy.